Plazomicin Sulfate
FDA-approved product (solution, intravenous), marketed as Zemdri.
- Registered studies
- 0
- Lab records
- 11
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Bacterial disease
- Pyelonephritis
- Urinary tract infection
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other aminoglycosides
- Anti-infective classification
- Classified as an existing antimicrobial.WHO ATC J01GB14
Repurposing investigation
Plazomicin Sulfate is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.
AI-predicted activity
AI prediction · nothing measured- MRSA58.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli57.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae90.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- M. tuberculosis47.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
No evidence found
The registry was searched and no registered study names this medicine.
Experimental
- K. pneumoniae: measured active in 11 of 11 lab records
Show the 11 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Plazomicin Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- AcalabrutinibExisting use: Cancer, Chronic lymphocytic leukemia, Mantle cell lymphoma and 1 more60.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Bremelanotide AcetateExisting use: Mental or behavioural disorder, Physiological sexual disorder, Sexual dysfunction60.8% AI-predicted activityagainst M. tuberculosis1 registered study
- EzogabineExisting use: Epilepsy, Seizure60.8% AI-predicted activityagainst M. tuberculosis32 registered studies
- EverolimusExisting use: Adenoma sebaceum, Anaplastic astrocytoma, Angiomyolipoma and 18 more60.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- ProbenecidExisting use: Gout60.7% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Leuprolide AcetateExisting use: Central precocious puberty, Metastatic prostate cancer, Neoplasm and 4 more60.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Atazanavir SulfateExisting use: HIV infection, HIV-1 infection, Infection and 1 more60.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Buclizine HydrochlorideExisting use: Allergic disease60.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- EstazolamExisting use: Insomnia60.6% AI-predicted activityagainst M. tuberculosis12 registered studies
- OlanzapineExisting use: Agitation, Bipolar disorder, Bipolar I disorder and 5 more60.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Rimegepant SulfateExisting use: Migraine disorder60.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- ChlorpropamideExisting use: Diabetes mellitus, Type 2 diabetes mellitus60.5% AI-predicted activityagainst M. tuberculosis6 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
No evidence found: the registry was searched and no registered study names this medicine.